Please assess the completion status of the following clinical trial:

Trial Title: Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed progressive supratentorial anaplastic astrocytoma or glioblastoma multiforme~* No multifocal disease or leptomeningeal dissemination of tumor~* No evidence of tumor crossing midline~* Limited intraventricular involvement~* Measurable unilateral mass at least 10 mm by contrast-enhanced MRI~* Received prior involved-field radiotherapy as a component of prior therapy~* Amenable to and in need of significant debulking~PATIENT CHARACTERISTICS:~Age~* 3 to 21~Performance status~* Karnofsky 60-100% OR~* Lansky 60-100%~Life expectancy~* More than 8 weeks~Hematopoietic~* Absolute neutrophil count greater than 1,000/mm3\*~* Platelet count greater than 100,000/mm3\*~* Hemoglobin greater than 8 g/dL (transfusions allowed) NOTE: \* Transfusion independent~Hepatic~* Bilirubin no greater than 1.5 times normal~* AST and ALT less than 3 times normal~* Albumin at least 2 g/dL~* No overt hepatic disease~Renal~* Creatinine clearance no greater than 1.5 times normal OR~* Glomerular filtration rate greater than 70 mL/min~* No overt renal disease~Cardiovascular~* No overt cardiac disease~Pulmonary~* No overt pulmonary disease~Other~* Neurological deficits must be stable for at least the past week~* No uncontrolled infection~* No known hypersensitivity to nitrosoureas or polyethylene glycol~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 6 months since prior bone marrow transplantation~* More than 2 weeks since prior colony-stimulating growth factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa)~Chemotherapy~* No more than 2 prior cytotoxic chemotherapy regimens~* No more than 3 prior chemotherapy regimens total~* More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered~* Prior systemic carmustine (or other nitrosourea) allowed provided patient did not experience non-hematopoietic grade III/IV toxicity~Endocrine therapy~* Concurrent dexamethasone allowed if on a stable dose for at least the past week~Radiotherapy~* See Disease Characteristics~* At least 3 months since prior radiotherapy~* No prior craniospinal irradiation for metastatic disease~Surgery~* See Disease Characteristics~* Prior biopsy or cytoreductive surgery allowed~Other~* Concurrent anticonvulsants allowed~* No other concurrent anticancer or investigational drugs

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).